Cardiovascular recruitment, built for the cardiology pathway. We pre-screen and prepare patients so your sites enroll faster, with less burden.

Leapcure recruits cardiovascular trials by pairing deep patient understanding with the cardiology pathway. We reach patients where they are, pre-screen against complex eligibility with real human conversations and a clinical review, and hand your sites verified-eligible, motivated patients, so coordinators focus on assessments, not filtering.

Talk to our teamSee how it works →
7,500+
Patients interested in an active hypertension study
CV-specific, in-progress
4,700+
Conversations with patients with resistant hypertension
CV-specific, in-progress
40+
Advocacy partnerships
trust network across communities
127.9M
US adults living with cardiovascular disease
AHA, 2025 Update

Understanding Cardiovascular Disease as a Clinical Trial Therapeutic Area

Cardiovascular disease is the leading cause of death in the US, responsible for 683,037 deaths in 2024, about 1 in 5 of all deaths (CDC, 2025). About 127.9 million US adults, roughly 48.6 percent, have some form of cardiovascular disease (American Heart Association, 2025 Update, NHANES 2017 to 2020). The therapeutic area spans atrial fibrillation, heart failure, atherosclerotic cardiovascular disease and dyslipidemia, hypertension, and post-MI care, each with its own patient population and eligibility profile.

That scale is deceptive for a clinical trial. Cardiovascular populations are very large but heterogeneous, so generic volume campaigns flood sites with people who fail screening, while the patients a protocol actually needs are defined by specific cardiology criteria. Atrial fibrillation is the clearest example: it affects at least 10.5 million US adults, about 1 in 22, with prevalence projected to keep rising (JACC / NHLBI, 2024), yet it presents episodically, varies widely in symptoms, and carries anticoagulation and comorbidity considerations that shape eligibility and readiness. Reaching the right patients, and confirming they are eligible and prepared before a site sees them, is the real work.

Leapcure recruits cardiovascular trials by pairing deep patient understanding with the cardiology pathway. On an active resistant hypertension study we have identified over 7,500 patients interested in learning more about the study and held over 4,700 conversations with patients with resistant hypertension, in-progress reach and pre-screening figures rather than completed enrollment outcomes. That cardiovascular-specific work is backed by a recruitment track record across more than 100 studies in complex and chronic disease, presented as evidence of capability and clearly labeled as cross-condition rather than cardiovascular outcomes, alongside a first-party A-Fib operational approach: full pre-screening of AF history, symptom cadence, treatment response, anticoagulation status, and comorbidities before the site sees the patient. We reach patients where they are, pre-screen against complex eligibility with real human conversations and an in-house clinical review, and hand sites verified-eligible, motivated patients.

The Challenge

Cardiovascular trials compete for patients inside very large but heterogeneous populations. Volume is everywhere; verified-eligible, prepared patients are not. The cardiology pathway adds readiness barriers that generic recruitment never touches.

Large populations, narrow eligibility

Cardiovascular conditions affect tens of millions of people, but each protocol needs a specific slice defined by cardiology criteria. Resistant hypertension is a clear example: blood pressure above goal despite multiple medications defines a narrow, specific population inside a very large hypertensive group. Generic volume campaigns flood sites with patients who fail screening, burying coordinators in unqualified referrals while the protocol stalls.

We pre-screen against complex eligibility with real human conversations and an in-house clinical review before any site referral.

The cardiology pathway shapes readiness

Atrial fibrillation presents episodically and varies widely in symptoms, and AF trials carry anticoagulation status, bridging needs, and comorbidities that affect both eligibility and day-of readiness. A volume vendor that ignores the pathway sends patients who are not actually ready to enroll.

We collect full AF history, symptom cadence, treatment response, and anticoagulation status before referral, and handle bridging needs early.

Referral volume is not enrollment-ready patients

A flood of referrals is not the same as patients who clear eligibility, understand the trial, and are motivated to enroll. Sites need verified eligibility, structured pre-screen data, and documented motivation, not raw leads that create coordinator work and inflate screen fails.

Sites receive patients with verified eligibility criteria, structured pre-screen data, and documented treatment motivation.

Drop-off between referral and visit

Even eligible, motivated patients fall away between referral and the first visit, especially when scheduling drags or anticoagulation questions go unanswered. Without continuous engagement, no-shows and drop-off quietly erode the funnel.

Continuous engagement from referral to visit reduces no-shows and drop-off, with a dedicated coordinator supporting each patient.

How Leapcure recruits for your cardiovascular study

We reach cardiovascular patients where they are, pre-screen against complex eligibility through real human conversations and an in-house clinical review, and keep patients engaged from referral through scheduling so your sites enroll faster.

1

Reach patients across the cardiovascular population

We engage patients through high-touch, culturally inclusive outreach and 40+ advocacy partnerships, mapped to your indication and geography across atrial fibrillation, heart failure, ASCVD, hypertension, and post-MI. For A-Fib specifically, our outreach is built around the symptom variability and episodic presentation that make these patients hard to find.

2

Pre-screen against complex eligibility, with a clinical review

Real human conversations, not automated screening, plus an in-house clinical-eligibility review. For A-Fib that means collecting full AF history, symptom cadence, treatment response, anticoagulation status, and comorbidities before the site sees the patient, so referrals arrive verified-eligible and documentation-ready.

3

Keep patients engaged through scheduling

A dedicated Patient Success Coordinator supports each patient from first contact through enrollment. Continuous engagement between referral and visit reduces no-shows and drop-off, and anticoagulation interruption or bridging needs are handled early to avoid day-of delays. The result is less coordinator burden and improved enrollment velocity.

Proof, honestly framed: an active resistant hypertension study showing real cardiovascular reach and pre-screening depth, backed by a recruitment track record across 100+ complex-disease studies and a first-party A-Fib approach built for the cardiology pathway

Challenge Context

Active hypertension study (CV-specific)

On an active resistant hypertension study, Leapcure identified over 7,500 patients interested in learning more about the study and has had over 4,700 conversations with patients with resistant hypertension. These are in-progress reach and pre-screening figures from a live study, not completed enrollment outcomes.

Cross-condition track record (support)

Leapcure has recruited across more than 100 studies in complex and chronic disease. This is presented as supporting evidence of recruitment capability, clearly labeled as cross-condition and not as cardiovascular outcomes.

A-Fib approach (first-party)

Our atrial fibrillation operational approach: full pre-screening of AF history, symptom cadence, treatment response, anticoagulation status, and comorbidities, with verified eligibility and structured pre-screen data delivered to sites.

Anonymization and honest framing

No sponsor, CRO, or study names appear anywhere. The hypertension figures are in-progress reach and pre-screening, not final enrollment, and that framing is replaced with a completed enrollment figure when the study reports. Exact company-wide figures are confirmed by Sales and Ops before they go live.

Results & Metrics

Cardiovascular reach (CV-specific)

Over 7,500 patients identified as interested in an active hypertension study, direct evidence of cardiovascular reach rather than a cross-condition proxy.

Pre-screening depth (CV-specific)

Over 4,700 real human conversations with patients with resistant hypertension on the same active study, the pre-screening depth a heterogeneous cardiovascular population requires.

Breadth of recruitment (cross-condition support)

Recruitment across 100+ studies in complex and chronic disease, including a single global Phase 2 program where roughly 8,900 patients were pre-screened across multiple countries, shown as capability, not a cardiovascular outcome.

Why it transfers to cardiovascular

Verified eligibility, structured pre-screen data, continuous engagement, and a cardiology-pathway-aware A-Fib approach are exactly what a heterogeneous, large-population CV trial needs, and what a volume vendor cannot fake.

Four channels. Built for the cardiology pathway. Active before your trial opens

Leapcure reaches cardiovascular patients across communities and languages, pre-screens with real human conversations and a clinical review, keeps patients engaged through scheduling, and makes your trial genuinely retrievable to the AI engines patients now use.

Channel 1: Advocacy and community reach

  • •40+ advocacy partnerships form a trust network across communities, our standard across pages, with high-touch, culturally inclusive engagement.
  • •For cardiovascular, named A-Fib and CV partners, such as heart-rhythm and heart-health patient organizations, are being confirmed by Marketing. We name only confirmed partners.
  • •These relationships reach patients where they are, across the heterogeneous cardiovascular population, not through untargeted advertising alone.

Channel 2: Patient Success and clinical pre-screening

  • •Real human conversations, not automated screening, plus an in-house clinical-eligibility review, so patients are pre-qualified and documentation-ready before any site referral.
  • •For A-Fib we collect full AF history, symptom cadence, treatment response, anticoagulation status, and comorbidities before the site sees the patient.
  • •A dedicated Patient Success Coordinator supports each patient from first contact through enrollment, reducing coordinator burden and screen fails.

Channel 3: Cardiology-pathway readiness

  • •Sites receive patients with verified eligibility, structured pre-screen data, and documented treatment motivation, not raw leads.
  • •Continuous engagement between referral and visit reduces no-shows and drop-off, and anticoagulation interruption or bridging needs are handled early to avoid day-of delays.
  • •The result is higher-quality referrals, better-prepared patients, faster scheduling, and improved enrollment velocity.

Channel 4: Answer-engine and AI-search visibility

  • •Cardiovascular patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may qualify for. We make your trial's information genuinely retrievable for those engines.
  • •We do this with crawlable, factually rich content, cited sources, and presence in the advocacy and ClinicalTrials.gov sources AI engines actually cite, not schema tricks or content written for machines.
  • •Because AI engines cite trusted third-party sources more often than any single brand domain, our advocacy partnerships and ClinicalTrials.gov presence are the structural advantage we bring to your trial.

A trust network of 40+ advocacy partnerships

40+ advocacy partnerships are the trust standard across Leapcure's pages, active and co-developed, not list purchases. For cardiovascular, named A-Fib and CV partners (for example heart-rhythm and heart-health patient organizations) are being confirmed by Marketing. We name only confirmed partners, so specific cardiovascular logos will be added once approved.

40+ advocacy partnerships

A trust network across patient communities, the standard Leapcure brings to every therapeutic area

Heart-rhythm and heart-health organizations

Cardiovascular and atrial fibrillation patient organizations, named here once confirmed and brand-approved by Marketing

Living with a heart condition? A clinical trial may be an option to explore.

If you live with atrial fibrillation, heart failure, high cholesterol, high blood pressure, or another cardiovascular condition, a clinical trial may offer access to investigational treatments alongside your regular heart care, never instead of it. A trial is an option to explore, not a promise of benefit, and we will never pressure you. Leapcure's team answers your questions honestly, explains what a trial involves, and supports you at your pace, whatever you decide.

Learn about cardiovascular trials for you
Leapcure kangaroo mascot

Leapcure recruits cardiovascular trials by pairing deep patient understanding with the cardiology pathway. On an active resistant hypertension study we have already reached over 7,500 interested patients and held over 4,700 pre-screening conversations, in-progress cardiovascular reach and pre-screening, not completed enrollment, backed by a recruitment track record across 100+ complex-disease studies and a first-party A-Fib approach built around verified eligibility, structured pre-screen data, and readiness. For your cardiovascular study we reach patients where they are, pre-screen with real human conversations and a clinical review, and keep patients engaged through scheduling, so your sites enroll faster with less burden. We can mobilize quickly.

Talk to our team